All articles by Justine Ra

Justine Ra

Justine Ra is a healthcare reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing coverage on neurology and neurodegenerative diseases. Justine holds a degree in English from The University of Michigan, Ann Arbor.

AbbVie diversifies oncology portfolio with $10.1 bn ImmunoGen acquisition

The acquisition allows AbbVie to establish its presence in the ovarian cancer market with Immunogen’s Elahere.

Acelyrin claims errors by CRO Fortrea after late-stage failure

A Phase IIb/III trial studying the company’s immunotherapy izokibep, failed to achieve statistical significance for its primary endpoint

Merz strengthens its global footprint with botulinum approval in Australian market

Merz’s drug Xeomin is already approved by the FDA and EMA to treat chronic sialorrhea or excessive drooling.

NeoImmuneTech bags orphan drug tag for IL-7 acute radiation syndrome treatment

NeoImmuneTech is developing NT-17, an IL-7 treatment, to promote rapid T-cell recovery in patients with acute radiation syndrome.

BMS strengthens NSCLC market share with ROS1 drug Augtyro

Augtyro (repotrectinib) is the only FDA-approved tumour kinase inhibitor (TKI) for ROS1-positive non-small cell lung cancer (NSCLC).

Orphelia pushes boundaries with regulatory barriers for pediatric indications

Orphelia has lined its discovery pipeline with a number of pediatric CNS and rare cancer indications.

Eli Lilly reiterates POINT acquisition plans with tender offer extension

Amidst POINT’s shareholder turbulence, Lilly is keen to move forward with the $1.4bn acquisition.

Alfasigma opens new doors in the US with Intercept acquisition

Alfasigma will also gain access to Intercept’s severe alcohol-associated hepatitis (sAH) drug INT-787 currently in a Phase IIa study.

NRx and Nephron join hands to formulate ketamine for depression

NRx gained FDA fast track designation for the development of NRX-100 as part of a treatment for acute suicidality.

Sangamo tightens the belt, cutting staff and assets to advance product pipeline

As per the latest restructuring plan, Sangamo will advance its programs using AAV capsid delivery, Nav1.7 program, and Prion therapies.